Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. - Wikidata - wikimedia - TriplyDB

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

http://www.wikidata.org/entity/Q34113955

about

Madurella mycetomatis is highly susceptible to ravuconazole Management of histoplasmosis.New and emerging antifungal agents: impact on respiratory infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Synthesis, Biological Evaluation and Molecular Docking of Certain Sulfones as Potential Nonazole Antifungal Agents.Newer antifungal agents.Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.

P2860

Q28539848-9715FD1C-F80E-47B7-9516-F86964C4EF6F Q34768480-7D8DB628-1785-44C9-82E4-8477D0208BDF Q35627629-0375CFD0-97C1-4F4E-A1EF-6A352E786534 Q36491819-21D6E9FC-0AF0-493D-B372-A099C46969F5 Q36669593-0D74C7CC-8660-4A1A-924F-0B8D3ABF3812 Q37119029-271BF67A-4BB3-4EB5-9504-985BC4BB6D4C Q37918556-3FF48E5C-D751-40C8-8770-9D35C2F4245E Q38799849-9B16F9E8-E776-4C0C-B649-089EB3F6F1D1 Q44855715-CC718057-443A-4E59-B2AF-C3B37FD5D98F Q46711208-B4328D77-C103-4CD5-9844-AE5E2A0260B8

P2860

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

http://www.wikidata.org/entity/Q34113955

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@ast

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@en

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@nl

type

label

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@ast

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@en

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@nl

prefLabel

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@ast

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@en

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@nl

P1433

Q34113955-981FBEE5-4612-4F68-83D5-57935FD24A21

P1476

Q34113955-08C5DFE7-8880-430B-AAAF-125FA99EDB3F

P2093

Q34113955-1033E5A6-E846-4339-B100-A36594905CFE

Q34113955-3C60A7B2-909B-4723-B23F-6B73939DE4D1

Q34113955-450AAD69-574A-4DE1-9200-142010386997

Q34113955-F96718D0-0337-41D1-AB65-4C85A6958748

P2860

Q34113955-142579E0-6A6C-4866-8631-4F1A74046DBD

Q34113955-167C9DEF-72D1-41C7-92D8-421AD4CD0BE2

Q34113955-1C19B384-081F-4329-AD0D-F6FDE1A13455

Q34113955-23E70D89-CEEE-4530-B7C7-7F530A4B0590

Q34113955-29DCCA73-CAB6-4BA3-B865-D9BE4BF6FC23

Q34113955-2EE054C7-FEFD-47C4-8AB8-5465D79C4136

Q34113955-44AD2DBF-B1CC-419A-9234-903BBAE14573

Q34113955-4959EF67-39C9-4440-9EAE-BDD714D692C0

Q34113955-6F3AE8B8-3A4B-469E-B4BF-18DFEB657AD1

Q34113955-86CFEDE5-647D-4E47-B9BC-5492C5D0132D

P304

Q34113955-63A8A915-9625-41C7-A1A0-BCB89A08B6EC

P31

Q34113955-A464CF2C-E12C-437A-B234-865969A8D23F

P356

Q34113955-1099DC0D-8870-4501-B03A-A42305D4692F

P407

Q34113955-07765D68-88CF-4D55-9698-E0DCCB743790

P433

Q34113955-5372FDFA-0D9E-415F-9A03-645475716EC7

P478

Q34113955-44B72C3D-9D69-4109-B5A1-9477C79F9B15

P577

Q34113955-8821007D-D012-4F2F-812E-61968B327325

P698

Q34113955-D6C87754-530F-43D6-ADD4-323B606097F2

P932

Q34113955-20FB0D5B-05EF-4ACE-A55D-5FA2402EAA62

P356

AAC.46.3.922-924.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

@en

P2093

Calderon L

http://www.w3.org/2001/XMLSchema#string

Clemons KV

http://www.w3.org/2001/XMLSchema#string

Martinez M

http://www.w3.org/2001/XMLSchema#string

Stevens DA

http://www.w3.org/2001/XMLSchema#string

P2860

Activities of sordarins in murine histoplasmosis

Efficacy of nikkomycin Z in the treatment of murine histoplasmosis

In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.

In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis

In vitro activity of a new oral triazole, BMS-207147 (ER-30346)

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.

Treatment of histoplasmosis with MK-991 (L-743,872)

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.

Histoplasmosis and blastomycosis.

P304

922-924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.3.922-924.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11850289

http://www.w3.org/2001/XMLSchema#string

P932

127511

http://www.w3.org/2001/XMLSchema#string